Sitemap

• Homepage
• Newsletter Invitation 082017
• Clinical Trials
• Disease Areas
  • Acute Myeloid Leukemia
  • Beta-thalassemia
  • Breast Cancer
  • Lung Cancer
  • Lymphoma
  • Myelodysplastic Syndromes
  • Multiple Myeloma
  • Pancreatic Cancer
• Molecules
  • AG-881 (Pan-IDH Inhibitor)
  • Azacitidine (DNA Methyltransferase Inhibitor)
  • CC-122
  • CC-486 (DNA Methyltransferase Inhibitor)
  • CC-90002 (Anti-CD47 Antibody)
  • Demcizumab (Anti-DLL4/Notch Pathway)
  • Durvalumab (PD-L1 Inhibitor)
    • FusIOn Trial Program
  • Enasidenib (AG-221; IDH2 Inhibitor)
  • Lenalidomide (IMiD® Agent)
  • Luspatercept (Modified Activin Receptor Type IIB Fusion Protein)
  • Marizomib (Proteasome Inhibitor)
  • nab-Paclitaxel (Albumin-Bound Microtubule Inhibitor)
  • OMP-305B83 (Anti-DLL4/VEGF Bispecific Antibody)
  • Pomalidomide (IMiD® Agent)
  • Romidepsin (Histone Deacetylase Inhibitor)
• Pathways
  • Immuno-Oncology
    • Activity of IMiD® Agents
    • Combining Hypomethylating and Immuno-Oncology Agents
    • Combining Chemotherapy and Immuno-Oncology Agents
    • Checkpoint Inhibition (PD-L1)
    • Macrophage Activation (CD47)
    • Chimeric Antigen Receptor T Cells (CAR-T)
    • Inducible T-Cell Costimulator (ICOS)
  • Epigenetics
    • DNA Methylation
    • Histone Modification
    • Isocitrate Dehydrogenase (IDH) Mutations
  • Protein Homeostasis
    • Cereblon/E3 Ligase Pathway
    • Pleiotropic Pathway Modification
    • Proteasome Pathway
    • Deubiquitinating Enzymes
  • Biotherapeutics and Novel Targets
    • Notch Signaling
    • Aberrant Smad2/3 Signaling
    • Albumin Mediated Delivery (nab Technology)
    • Cell Signaling
• Pipeline
• Research Partners
  • Alliance Partners
  • Myeloma Genome Project
  • Multiple Myeloma DREAM Challenge
• Resources
  • Celgene Medical Information
  • Physician Perspective
  • The Celgene Story
  • Newsletter
  • Contact